2023 World Conference on Lung Cancer (Posters)-EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study

EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study - PDF(Abstract)

Back to course

Pdf Summary

This is a summary of a study presented at the WCLC 2023 conference. The study aimed to evaluate the efficacy of combination therapy with erlotinib and ramucirumab in patients with metastatic non-small cell lung cancer (NSCLC) who had previously been treated with EGFR-TKI.<br /><br />The study included 8 patients who had received the combination therapy between January 2021 and June 2022. The median age of the patients was 69 years, with 5 women included. The median performance status (PS) was 1, and the median line of administration was 4.5. Six patients had exon 19 del EGFR gene mutation, and 2 patients were positive for T790M mutation. Four patients had received osimertinib, and four had received immune checkpoint inhibitors.<br /><br />The study found that the combination therapy with erlotinib and ramucirumab showed some efficacy as late-line therapy in patients previously treated with EGFR-TKI. The response rate was 25%, disease control was achieved in 75% of patients, and the median progression-free survival was 273 days.<br /><br />These results suggest that the combination therapy could be a viable treatment option for patients with metastatic NSCLC who have previously been treated with EGFR-TKI. However, further research and larger studies are needed to confirm these findings.<br /><br />In conclusion, this retrospective observational study demonstrated that combination therapy with erlotinib and ramucirumab showed some efficacy in patients previously treated with EGFR-TKI. These findings contribute to the knowledge on targeted therapy for metastatic NSCLC and provide insights for further research in this field.

Asset Subtitle

Tomoki Tamura

Meta Tag

Speaker Tomoki Tamura

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

combination therapy

erlotinib

ramucirumab

metastatic non-small cell lung cancer

NSCLC

EGFR-TKI

late-line therapy

response rate

disease control

progression-free survival